The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
Your search for major depressive disorder returned 3 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
The FDA has approved Rexulti (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer disease.
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
Latest News Your top articles for MondayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses